Diabetes drug major USV eyes niche therapies abroad, targets Rs 50 billion sales

 
(Ref: Business Standard)
  • USV plans to increase its focus on biosimilars and niche low-competition products in an effort to boost sales to Rs. 5000 crore, as reported Business Standard Friday.

  • Last month, the European Medical Agency accepted USV's application requesting approval of pegfilgrastim, a biosimilar of Amgen's Neulasta.

  • "In the US market we do about $25 million of net sales," said managing director Prashant Tewari, adding "so that will grow since we have two three important products. We will take pegfilgrastim to the US as well."

  • USV's portfolio also includes proprietary drugs such as vildagliptin, which was licenced from Novartis.

  • Meanwhile, the company must overcome regulatory issues, as the FDA issued a warning letter for its Daman facility for violations of good manufacturing practices.

  • "Remediation has been done from our side," noted Tewari, adding "we had re-inspection, and in our view it was very good. Now we are awaiting a feedback."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>